Motoko Nagata

Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation and structure–activity relationships. Part 2

Takao Horiuchi, Motoko Nagata, Mayumi Kitagawa et al. · Bioorganic & Medicinal Chemistry · 2009 · 70 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Novel Thieno[2,3-d]pyrimidin-4-yl Hydrazone-Based Cyclin-Dependent Kinase 4 Inhibitors: Synthesis, Biological Evaluation and Structure-Activity Relationships

Takao Horiuchi, Yasuyuki Takeda, Noriyasu Haginoya et al. · Chemical and Pharmaceutical Bulletin · 2011 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Nuclear and cytoplasmic c‐Ski differently modulate cellular functions

Motoko Nagata, Kouichiro Goto, Shogo Ehata et al. · Genes to Cells · 2006 · 38 citations

Life Sciences, Cell Biology, Molecular Biology +16

Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models

Hirokazu Suzuki, Shotaro Nagase, C. Saito et al. · Molecular Cancer Therapeutics · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17

c‐Ski activates MyoD in the nucleus of myoblastic cells through suppression of histone deacetylases

Norihiko Kobayashi, Kouichiro Goto, Kana Horiguchi et al. · Genes to Cells · 2007 · 28 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17